Evidence map›Paper›PMID 34194582›Full record

ArticleDisease markers2021

Heyang Zhang, Xiaoxue Wang, Shibo Li, Xianfu Wang, Xianglan Lu, Ming Li, Hua Wang, Ying Liu, Hui Pang, Lijun Zhang

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Heyang ZhangDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaoxue WangDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Shibo LiDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Xianfu WangDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Xianglan LuDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Ming LiDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Hua WangDivision of Genetics, Department of Pediatrics, Loma Linda University, Loma Linda, CA, USA.
Ying LiuDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Hui PangDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID https://orcid.org/0000-0003-1605-7127
Lijun ZhangDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0000-0002-9821-1863
University of Oklahoma Health Sciences Center · USFirst Hospital of China Medical University · CNLoma Linda University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Double minute chromosomes (dmins) are a form of gene amplification presenting as small spherical paired chromatin bodies. Dmins are rare in hematologic malignancies and are generally associated with a poor prognosis. Some case reports identified

Indexed as

Gene AmplificationComparative Genomic Hybridizationfms-Like Tyrosine Kinase 3HumansIn Situ Hybridization, FluorescenceKaryotypingLeukemia, Myelomonocytic, ChronicMaleMiddle AgedRing ChromosomesFLT3 protein, humanfms-Like Tyrosine Kinase 3

Identifiers

PMID34194582
PMCPMC8203365
OpenAlexW3168903230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.